<?xml version="1.0" ?>
<TimeML xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://timeml.org/timeMLdocs/TimeML_1.2.1.xsd">

<DOCID>695202423411</DOCID>

<DCT><TIMEX3 tid="t0" type="DATE" value="20170129" temporalFunction="false" functionInDocument="CREATION_TIME">January 29, 2017</TIMEX3></DCT>

<TITLE>Scientists inhibit brain tumor cell growth, p...</TITLE>


<TEXT>
Glioblastoma is a particularly aggressive form of brain cancer that can be difficult to <EVENT eid="e1" class="OCCURRENCE">treat</EVENT>. New research, however, may have <EVENT eid="e2" class="OCCURRENCE">found</EVENT> a drug that can <EVENT eid="e3" class="OCCURRENCE">inhibit</EVENT> the protein <EVENT eid="e4" class="OCCURRENCE">driving</EVENT> its growth. Researchers may have <EVENT eid="e5" class="OCCURRENCE">found</EVENT> a way to <EVENT eid="e6" class="OCCURRENCE">inhibit</EVENT> the growth of brain tumors, here <EVENT eid="e7" class="OCCURRENCE">shown</EVENT> in an MRI scan. Glioblastomas are tumors that form out of the "sticky," supportive tissue of the brain and spinal cord. 

Most of the time, glioblastomas are aggressive <EVENT eid="e8" class="STATE">malignant</EVENT>; they are made of many different types of cells that reproduce very quickly and <EVENT eid="e9" class="OCCURRENCE">receive</EVENT> a significant blood supply. The 5-year survival rate is <EVENT eid="e10" class="I_STATE">estimated</EVENT> to be less than 10 percent. 

Glioblastoma can be <EVENT eid="e11" class="I_STATE">difficult</EVENT> to <EVENT eid="e12" class="OCCURRENCE">treat</EVENT> because of the heterogenous nature of its cells. Some of the cells may <EVENT eid="e13" class="OCCURRENCE">respond</EVENT> to therapy while others may not. 

Typically, treatment includes a combination of surgery, radiation, and chemotherapy. So far, this has <EVENT eid="e14" class="OCCURRENCE">resulted</EVENT> in a median survival of about <TIMEX3 tid="t1" type="DURATION" value="P2Y">2 to 3 years</TIMEX3> for patients receiving standard treatment. 

Patients with more severe forms of glioblastoma, who <EVENT eid="e15" class="OCCURRENCE">receive</EVENT> a combination of drugs and radiation therapy, usually survive for an average of <TIMEX3 tid="t2" type="DURATION" value="P146M">14.6 months</TIMEX3>, and the <TIMEX3 tid="t3" type="DURATION" value="P2Y">2-year</TIMEX3> survival rate is approximately 30 percent. Little can be <EVENT eid="e16" class="OCCURRENCE">done</EVENT> to <EVENT eid="e17" class="OCCURRENCE">treat</EVENT> recurrent glioblastoma. 

In this context, more and more researchers are <EVENT eid="e18" class="OCCURRENCE">exploring</EVENT> genetic options for treatment. Recent studies have <EVENT eid="e19" class="OCCURRENCE">pointed</EVENT> to mutations in the receptor tyrosine kinase (RTK) genes as the key driver of glioblastoma, but clinical trials aimed specifically at <EVENT eid="e20" class="OCCURRENCE">neutralizing</EVENT> these driver <EVENT eid="e21" class="OCCURRENCE">mutations</EVENT> were not successful in <EVENT eid="e22" class="OCCURRENCE">treating</EVENT> this form of cancer. 

However, researchers from the Peter O'Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center may have <EVENT eid="e23" class="OCCURRENCE">found</EVENT> a way to <EVENT eid="e24" class="OCCURRENCE">inhibit</EVENT> glioblastoma cells. 

Their findings were <EVENT eid="e25" class="OCCURRENCE">published</EVENT> in the journal Cell Reports. 

The team - <EVENT eid="e26" class="OCCURRENCE">co-led</EVENT> by Dr. Robert Bachoo, of the Annette G. Strauss Center for Neuro-Oncology at University of Texas Southwestern Medical Center, and Dr. Ralf Kittler, an assistant professor of pharmacology in the Eugene McDermott Center for Human Growth and Development - successfully <EVENT eid="e27" class="OCCURRENCE">used</EVENT> a drug to <EVENT eid="e28" class="OCCURRENCE">target</EVENT> different proteins that drive the growth of glioblastoma tumors. 

Mithramycin inhibits glioblastoma-driving transcription factors 

The new study suggests that so far, researchers have mistakenly <EVENT eid="e29" class="OCCURRENCE">focused</EVENT> on RTK gene mutations, which are only responsible for <EVENT eid="e30" class="OCCURRENCE">starting</EVENT> tumor growth, not for the continued <EVENT eid="e31" class="OCCURRENCE">growth</EVENT> of glioblastoma. 

"Our work <EVENT eid="e32" class="OCCURRENCE">shows</EVENT> that the gene mutations which the pharmaceutical industry and clinicians have been <EVENT eid="e33" class="OCCURRENCE">focusing</EVENT> on are essential only for starting tumor <EVENT eid="e34" class="OCCURRENCE">growth</EVENT>. Once the tumor has <EVENT eid="e35" class="OCCURRENCE">advanced</EVENT> to the stage where patients seek treatment, these mutations are no longer <EVENT eid="e36" class="OCCURRENCE">required</EVENT> for continued tumor growth; they are in effect redundant," <EVENT eid="e37" class="REPORTING">explains</EVENT> co-senior author Dr. Bachoo. 

Instead of the RTK genes, the new study <EVENT eid="e38" class="OCCURRENCE">found</EVENT> three transcription factors to be <EVENT eid="e39" class="STATE">responsible</EVENT> for <EVENT eid="e40" class="OCCURRENCE">glioblastoma</EVENT>: Sox2, Olig2, and Zeb1. As co-senior author Dr. Kittler <EVENT eid="e41" class="OCCURRENCE">explains</EVENT>, the study <EVENT eid="e42" class="OCCURRENCE">shows</EVENT> that these "neurodevelopmental transcription factors (master proteins that regulate the activity of hundreds of genes during normal brain development) are reactivated to <EVENT eid="e43" class="OCCURRENCE">drive</EVENT> the <EVENT eid="e44" class="OCCURRENCE">growth</EVENT> of glioblastoma." 

In their study, Dr. Kittler, Dr. Bachoo, and team <EVENT eid="e45" class="OCCURRENCE">found</EVENT> the drug mithramycin to <EVENT eid="e46" class="OCCURRENCE">inhibit</EVENT> these transcription factors. "We can <EVENT eid="e47" class="OCCURRENCE">inhibit</EVENT> these transcription factors and <EVENT eid="e48" class="OCCURRENCE">prevent</EVENT> further tumor growth with the chemotherapy drug mithramycin, a drug that has not been in clinical use for <TIMEX3 tid="t4" type="DURATION" value="PXY">years</TIMEX3> due to its side effects. Our discovery has the potential for the <EVENT eid="e49" class="OCCURRENCE">development</EVENT> of a new therapy that may <EVENT eid="e50" class="OCCURRENCE">increase</EVENT> survival time for glioblastoma patients." 

Dr. Ralf Kittler

"These findings <EVENT eid="e51" class="OCCURRENCE">change</EVENT> our fundamental understanding of the molecular basis of glioblastoma, and how to <EVENT eid="e52" class="OCCURRENCE">treat</EVENT> it," adds Dr. Bachoo. "We may have <EVENT eid="e53" class="OCCURRENCE">identified</EVENT> a set of critical genes we can <EVENT eid="e54" class="OCCURRENCE">target</EVENT> with drugs that are shared across nearly all glioblastomas." 

However, the scientists <EVENT eid="e55" class="REPORTING">warn</EVENT> that mithramycin may <EVENT eid="e56" class="OCCURRENCE">cause</EVENT> liver toxicity in a number of patients, and that <EVENT eid="e57" class="OCCURRENCE">repurposing</EVENT> the drug to <EVENT eid="e58" class="OCCURRENCE">treat</EVENT> glioblastoma could <EVENT eid="e59" class="OCCURRENCE">take</EVENT> <TIMEX3 tid="t5" type="DATE" value="X">several</TIMEX3> years. 

Learn how cancer may not mainly be down to 'bad luck'.
</TEXT>


<MAKEINSTANCE eiid="ie49" eventID="e49" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie44" eventID="e44" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie39" eventID="e39" pos="ADJECTIVE" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie38" eventID="e38" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie19" eventID="e19" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie18" eventID="e18" pos="VERB" tense="PRESENT" aspect="PROGRESSIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie35" eventID="e35" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie34" eventID="e34" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie33" eventID="e33" pos="VERB" tense="PRESENT" aspect="PERFECTIVE_PROGRESSIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie32" eventID="e32" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie31" eventID="e31" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie30" eventID="e30" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie11" eventID="e11" pos="ADJECTIVE" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie10" eventID="e10" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie13" eventID="e13" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie12" eventID="e12" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie15" eventID="e15" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie14" eventID="e14" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie17" eventID="e17" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie16" eventID="e16" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie42" eventID="e42" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie59" eventID="e59" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="CAN" />
<MAKEINSTANCE eiid="ie58" eventID="e58" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie55" eventID="e55" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie54" eventID="e54" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie57" eventID="e57" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie56" eventID="e56" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie51" eventID="e51" pos="UNKNOWN" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie50" eventID="e50" pos="VERB" tense="NONE" aspect="NONE" polarity="POS" modality="MAY" />
<MAKEINSTANCE eiid="ie53" eventID="e53" pos="VERB" tense="NONE" aspect="PERFECTIVE" polarity="POS" modality="WOULD" />
<MAKEINSTANCE eiid="ie52" eventID="e52" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie37" eventID="e37" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie36" eventID="e36" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie40" eventID="e40" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie43" eventID="e43" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie41" eventID="e41" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie9" eventID="e9" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie8" eventID="e8" pos="ADJECTIVE" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie5" eventID="e5" pos="VERB" tense="NONE" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie4" eventID="e4" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie7" eventID="e7" pos="VERB" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie6" eventID="e6" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie1" eventID="e1" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie3" eventID="e3" pos="UNKNOWN" tense="FUTURE" aspect="NONE" polarity="POS" modality="COULD" />
<MAKEINSTANCE eiid="ie2" eventID="e2" pos="VERB" tense="NONE" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie24" eventID="e24" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie25" eventID="e25" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie26" eventID="e26" pos="VERB" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie27" eventID="e27" pos="VERB" tense="PRESENT" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie20" eventID="e20" pos="VERB" tense="PRESPART" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie21" eventID="e21" pos="NOUN" tense="NONE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie22" eventID="e22" pos="VERB" tense="PRESPART" aspect="NONE" polarity="NEG" modality="N/A" />
<MAKEINSTANCE eiid="ie23" eventID="e23" pos="VERB" tense="NONE" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie46" eventID="e46" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie45" eventID="e45" pos="VERB" tense="PAST" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie28" eventID="e28" pos="VERB" tense="INFINITIVE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie29" eventID="e29" pos="UNKNOWN" tense="PRESENT" aspect="PERFECTIVE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie47" eventID="e47" pos="VERB" tense="FUTURE" aspect="NONE" polarity="POS" modality="N/A" />
<MAKEINSTANCE eiid="ie48" eventID="e48" pos="UNKNOWN" tense="PAST" aspect="NONE" polarity="NEG" modality="N/A" />

<TLINK lid="TL1" eventInstanceID="ie54" relatedToEventInstance="ie53" relType="INCLUDES" />
<TLINK lid="TL0" eventInstanceID="ie42" relatedToEventInstance="ie41" relType="SIMULTANEOUS" />
<TLINK lid="TL3" timeID="t2" relatedToEventInstance="ie15" relType="INCLUDES" />
<TLINK lid="TL2" eventInstanceID="ie48" relatedToEventInstance="ie47" relType="AFTER" />
</TimeML>
